A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease
Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…Effect of Allogeneic Bone-Marrow Derived Mesenchymal Stem Cell Therapy on Quality of Life in Patients with Parkinson’s Disease
Objective: To assess the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on the quality of life (QoL) of patients with…A Systematic Site Selection Approach to Ensure Efficient and Diverse Participant Recruitment to a Large-Scale Multi-Arm, Multi-Stage Platform Trial for Parkinson’s
Objective: To select up to 40 delivery sites to successfully recruit and retain a participant population representative of people with Parkinson’s disease (PwP) in the…EJS ACT-PD: An Ongoing Initiative to Support Innovation and Sustainability of a Multi-Arm, Multi-Stage Platform Trial for Parkinson’s Disease
Objective: To provide continued consortium expertise to provide ongoing innovation and long-term sustainability in a multi-arm, multi-stage (MAMS) disease modification trial for Parkinson’s disease (PD).…Ecologically Valid, Ambient, Longitudinal, and Unbiased Assessment of Treatment Efficacy in Parkinson’s Disease (EVALUATE-PD)
Objective: To determine the feasibility of using in-home digital biomarkers (DBs) and activity monitoring for clinical trials and studies of early Parkinson’s Disease (PD) and…A Phase 1b Study to Investigate Safety and Tolerability of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson’s Disease
Objective: To investigate safety and tolerability of repeated subcutaneous (s.c.) doses of HER-096 in subjects with Parkinson’s disease. Background: HER-096 is a retro-inverso isomerized peptide…ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy
Objective: Evaluate the efficacy and safety of ATH434 treatment in individuals with MSA Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder without…A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease
Objective: To describe the innovative Phase 2 study design aimed to investigate vent-02 in the treatment of PD. Background: NLRP3 hyperactivation plays a critical role…Bidirectional Relationships Between Frailty and DNAm Age Acceleration and its Mediation Effects on Physical Disability and Mortality
Objective: This study aims to investigate the bidirectional associations between frailty and DNA methylation (DNAm) age acceleration (AgeAccel), and further test whether epigenetic aging mediates…PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To evaluate the effect of prasinezumab on slowing down disease progression in participants with early-stage Parkinson’s disease (PD) on stable symptomatic medication. Background: Prasinezumab…
- 1
- 2
- 3
- …
- 19
- Next Page »